Oxford BioTherapeutics Email Formats
Biotechnology Research • 
Oxford, England, United Kingdom • 51-100 Employees
Oxford BioTherapeutics Email Formats
Oxford BioTherapeutics uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@oxfordbiotherapeutics.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@oxfordbiotherapeutics.com | 100% |
Key Contacts at Oxford BioTherapeutics
Yu-Tzu Tai
Director - Adc & Translational Science
Somdatta Basu
Director
Belinda Cairns
Director Of Histopathology
Ailan Lu
Associate Director
Chuck Hannum
Senior Director, Protein Sciences
Stephen Blance
Director Of Intellectual Property
Arnima Bisht
Senior Director
Company overview
| Headquarters | The Schrodinger Building, Oxford Science Park, Suite A, Second Floor, Oxford, OX4 4GE, GB |
| Phone number | +441235861770 |
| Websites | |
| SIC | 873 |
| Keywords | Biotechnology, Cancer, Oncology, Proteomics, Antibody-Drug Conjugates, Immune-Oncology, Protein Target Discovery |
| Founded | 2004 |
| Employees | 51-100 |
| Socials |
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Oxford BioTherapeutics has 26 employees across 8 departments.
Departments
Number of employees
Oxford BioTherapeutics Tech Stack
Discover the technologies and tools that power Oxford BioTherapeutics's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Security
Video players
JavaScript libraries
CDN
JavaScript libraries
CMS
JavaScript libraries
Programming languages
Analytics
JavaScript frameworks
France
Poland
South Africa
Spain
Belgium
Frequently asked questions
4.8
40,000 users
